These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 24064957)

  • 21. Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer.
    Keehn A; Gartrell B; Schoenberg MP
    Future Oncol; 2016 Dec; 12(23):2673-2682. PubMed ID: 27609194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses.
    Mundhada S; Shaw J; Mori S; Savary CA; Mullen CA
    Leuk Lymphoma; 2005 Apr; 46(4):571-80. PubMed ID: 16019486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.
    Draganov DD; Santidrian AF; Minev I; Nguyen D; Kilinc MO; Petrov I; Vyalkova A; Lander E; Berman M; Minev B; Szalay AA
    J Transl Med; 2019 Mar; 17(1):100. PubMed ID: 30917829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status and future prospects of peptide-based cancer vaccines.
    Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
    Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of antitumor immunity by semi-allogeneic and fully allogeneic electrofusion products of tumor cells and dendritic cells.
    Siders WM; Garron C; Shields J; Kaplan JM
    Clin Transl Sci; 2009 Feb; 2(1):75-9. PubMed ID: 20443871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic cancer vaccines: an emerging treatment option.
    King SE
    Clin J Oncol Nurs; 2004 Jun; 8(3):271-8. PubMed ID: 15208821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cancer Vaccine Focused on Neoantigens].
    Shindo Y; Hazama S; Nagano H
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1367-1371. PubMed ID: 31530772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple-purpose immunotherapy for cancer.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Biomed Pharmacother; 2015 Dec; 76():24-9. PubMed ID: 26653546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.
    Aerts JGJV; de Goeje PL; Cornelissen R; Kaijen-Lambers MEH; Bezemer K; van der Leest CH; Mahaweni NM; Kunert A; Eskens FALM; Waasdorp C; Braakman E; van der Holt B; Vulto AG; Hendriks RW; Hegmans JPJJ; Hoogsteden HC
    Clin Cancer Res; 2018 Feb; 24(4):766-776. PubMed ID: 29233904
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapeutic cancer vaccines: a long and winding road to success.
    Baxevanis CN; Papamichail M; Perez SA
    Expert Rev Vaccines; 2014 Jan; 13(1):131-44. PubMed ID: 24224539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel immunotherapies.
    Yi Q
    Cancer J; 2009; 15(6):502-10. PubMed ID: 20010170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
    Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
    Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA vaccines for cancer.
    Boyd D; Hung CF; Wu TC
    IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical development of Listeria monocytogenes-based immunotherapies.
    Le DT; Dubenksy TW; Brockstedt DG
    Semin Oncol; 2012 Jun; 39(3):311-22. PubMed ID: 22595054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities.
    Patel RB; Baniel CC; Sriramaneni RN; Bradley K; Markovina S; Morris ZS
    Brachytherapy; 2018; 17(6):995-1003. PubMed ID: 30078541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine.
    Thomas MC; Greten TF; Pardoll DM; Jaffee EM
    Hum Gene Ther; 1998 Apr; 9(6):835-43. PubMed ID: 9581906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunizing against breast cancer: a new swing for an old sword.
    Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A
    Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Sondak VK; Sabel MS; Mulé JJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
    Aguilar LK; Guzik BW; Aguilar-Cordova E
    J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.